A Method to assess Biochemical Activity of Liver Cells during Clinical Application of Extracorporeal Hybrid Liver Support

@article{Mundt2002AMT,
  title={A Method to assess Biochemical Activity of Liver Cells during Clinical Application of Extracorporeal Hybrid Liver Support},
  author={Anja Pamela Mundt and Gero Puhl and Andrea R. M{\"u}ller and Igor M. Sauer and Christian M{\"u}ller and R Richard and C. Fotopoulou and R Doll and Gereon G{\"a}belein and Wolfgang Höhn and Rafael Hofbauer and Peter Neuhaus and J{\"o}rg C. Gerlach},
  journal={The International Journal of Artificial Organs},
  year={2002},
  volume={25},
  pages={542 - 548}
}
  • A. Mundt, G. Puhl, +10 authors J. Gerlach
  • Published 1 June 2002
  • Biology, Medicine
  • The International Journal of Artificial Organs
Biochemical activity of a hybrid liver support system based on porcine liver cells was investigated in patients suffering from acute liver failure, coma stage III-IV. Patient plasma was drawn systemically and after circulation through the bioreactor at four hour intervals. A method is used that takes into account the rate of plasma flow and the differences in plasma concentration systemically and after circulation through the liver support system to determine the net release or uptake of… 
Bioreactors for Extracorporeal Liver Support
TLDR
The Modular Extracorporeal Liver Support (MELS) concept proposes an integrative approach for the treatment of hepatic failure with appropriate extracorpreal therapy units, tailored to suit the actual clinical needs of each patient.
Clinical Application of Bioartificial Liver Support Systems
TLDR
Bioartificial liver therapy for bridging patients with ALF to liver transplantation or liver regeneration is promising, and its clinical value awaits further improvement of BAL devices, replacement of hepatocytes of animal origin by human hepatocytes, and assessment in controlled clinical trials.
Extracorporeal Liver Support: Porcine or Human Cell Based Systems?
TLDR
The hypothesis of this paper is that with appropriate logistics and four-compartment bioreactor technology, cells from human liver transplant discards can serve the demand for cell-based therapy, including extracorporeal liver support.
Acute-on-chronic liver failure: extracorporeal liver assist devices
TLDR
Liver support systems are safe and well tolerated when used in management of patients with ACLF and should continue in controlled clinical trials to explore their role in bridging patients to liver transplantation or recovery in well defined patient groups.
Bridging a Patient with Acute Liver Failure to Liver Transplantation by the AMC-Bioartificial Liver
TLDR
This patient with ALF due to acute HBV infection was treated for 35 h by two AMC-BAL treatments and was bridged to OLT and possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.
Issues in Bioartificial Liver Support Therapy for Acute Liver Failure
TLDR
The clinical efficacy of both AL (detoxification) and BAL (cell-based metabolic support) will be verified in the next 10 years, however, the clinical timing and indication will be different for the two systems: detoxification approaches will be employed earlier in the disease progression and, most likely, for AoCLF while BAL support will be used to support ALF patients andwill be used when the disease continues to progress despite best medical therapy and detoxification.
Lidocaine/monoethylglycinexylidide test, galactose elimination test, and sorbitol elimination test for metabolic assessment of liver cell bioreactors.
TLDR
Two methods for dispensing test substances, bolus administration and continuous, steady-state administration are demonstrated, which enables a better view of culture health and the time dependency of cellular function, whereas bolu administration is more flexible.
Large animal models of fulminant hepatic failure in artificial and bioartificial liver support research.
TLDR
An overview is given of the different models and their advantages and disadvantages and suggestions are made for the most suitable large animal model to test liver support systems.
Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure.
TLDR
The efficacy of MSCs, when cocultured with hepatocytes, to provide combination hepatic and antiinflammatory therapy in the setting of ALF is demonstrated and the importance of nonparenchymal cells in the cellular composition of LADs is demonstrated, strongly support the integration of M SCs into hepatocyte-coculture-based L ADs as a potential destination therapy for ALF.
Bioartificial liver systems: why, what, whither?
TLDR
A novel bioreactor design is described that closely mimics the native liver cell environment and is easily scaled from microscopic (<1 ml cells) to clinical size, while maintaining the same local cell environment throughout theBioreactor.
...
1
2
3
...

References

SHOWING 1-10 OF 37 REFERENCES
Development of a Hybrid Bioartificial Liver
TLDR
Plasma perfusion through a system consisting of a charcoal column and matrix-attached porcine hepatocytes had significant beneficial effects in animals with liver failure and was well tolerated by a patient with liver Failure.
Development of a Hybrid Liver Support System: A Review
  • J. Gerlach
  • Chemistry, Medicine
    The International journal of artificial organs
  • 1996
TLDR
A five-step technique for primary liver cell isolation has been introduced in order to address larger scale procurement of hepatocytes, and a complete hybrid liver support system for human studies was introduced and applied clinically.
Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency.
The results of intensive therapy and temporary organ substitution by hemoperfusion through a suspension of active hepatocytes in 126 patients suffering from acute hepatic insufficiency (AHI) induced
Extracorporeal liver support: cell-based therapy for the failing liver.
  • N. Sussman, J. Kelly
  • Medicine
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1997
TLDR
Theoretical and practical problems in developing an extracorporeal liver-assist device (ELAD) are addressed and the future role of extracordoreal liver support in the management of liver failure is suggested.
Successful application of extracorporeal liver perfusion: a technology whose time has come.
TLDR
These studies suggest that, 30 yr after initial clinical trials, ECLP can be applied safely without the need for arterial access as a bridge to transplantation and potentially, to evaluate the "usability" of questionable donor organs.
High yield hepatocyte isolation from pig livers for investigation of hybrid liver support systems: influence of collagenase concentration and body weight.
TLDR
A new method of open-loop and recirculating perfusion in five steps using both the portal venous and the hepatic arterial vascular systems has been developed and appears to be reproducible and safe.
Comparison of four methods for mass hepatocyte isolation from pig and human livers.
TLDR
The 5-step method with combined arterial and portal vein perfusion developed for pig liver was used for mass human liver cell isolation with a minimum viability of 57% and a minimum yield of 58% wet weight.
High Volume Plasma Exchange in Fulminant Hepatic Failure
TLDR
Plasmapheresis may be used to keep patients with definite liver failure clinically stable until a transplant can be performed and may be considered in acute liver failure in patients with residual liver function before transplantation is finally decided.
Liver Assist Systems: State of the Art
TLDR
The authors review the current status of liver assist systems and summarize their clinical experience with a xenogeneic cell based-bioartificial liver.
Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.
TLDR
A bioartificial liver to treat patients with severe liver failure until they can be either transplanted or recover spontaneously and the authors' clinical experience with the BAL has yielded encouraging results.
...
1
2
3
4
...